234 related articles for article (PubMed ID: 18079436)
21. Isolation and Detection of Pathological Tau Species in a Tauopathy Mouse Model.
Singh AK; Selvarasu K; Durairajan SSK
Methods Mol Biol; 2024; 2761():317-328. PubMed ID: 38427247
[TBL] [Abstract][Full Text] [Related]
22. Kinesin-1 transport reductions enhance human tau hyperphosphorylation, aggregation and neurodegeneration in animal models of tauopathies.
Falzone TL; Gunawardena S; McCleary D; Reis GF; Goldstein LS
Hum Mol Genet; 2010 Nov; 19(22):4399-408. PubMed ID: 20817925
[TBL] [Abstract][Full Text] [Related]
23. Early behavioural markers of disease in P301S tau transgenic mice.
Scattoni ML; Gasparini L; Alleva E; Goedert M; Calamandrei G; Spillantini MG
Behav Brain Res; 2010 Mar; 208(1):250-7. PubMed ID: 20004218
[TBL] [Abstract][Full Text] [Related]
24. Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility.
Sahara N; Lewis J; DeTure M; McGowan E; Dickson DW; Hutton M; Yen SH
J Neurochem; 2002 Dec; 83(6):1498-508. PubMed ID: 12472903
[TBL] [Abstract][Full Text] [Related]
25. Amyloid β accelerates phosphorylation of tau and neurofibrillary tangle formation in an amyloid precursor protein and tau double-transgenic mouse model.
Seino Y; Kawarabayashi T; Wakasaya Y; Watanabe M; Takamura A; Yamamoto-Watanabe Y; Kurata T; Abe K; Ikeda M; Westaway D; Murakami T; Hyslop PS; Matsubara E; Shoji M
J Neurosci Res; 2010 Dec; 88(16):3547-54. PubMed ID: 20936700
[TBL] [Abstract][Full Text] [Related]
26. Tyrosine phosphorylation of tau accompanies disease progression in transgenic mouse models of tauopathy.
Bhaskar K; Hobbs GA; Yen SH; Lee G
Neuropathol Appl Neurobiol; 2010 Oct; 36(6):462-77. PubMed ID: 20609109
[TBL] [Abstract][Full Text] [Related]
27. A novel triple repeat mutant tau transgenic model that mimics aspects of pick's disease and fronto-temporal tauopathies.
Rockenstein E; Overk CR; Ubhi K; Mante M; Patrick C; Adame A; Bisquert A; Trejo-Morales M; Spencer B; Masliah E
PLoS One; 2015; 10(3):e0121570. PubMed ID: 25803611
[TBL] [Abstract][Full Text] [Related]
28. Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy.
Schaeffer V; Lavenir I; Ozcelik S; Tolnay M; Winkler DT; Goedert M
Brain; 2012 Jul; 135(Pt 7):2169-77. PubMed ID: 22689910
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of heme oxygenase 1 causes cognitive decline and affects pathways for tauopathy in mice.
Wang D; Hui Y; Peng Y; Tang L; Jin J; He R; Li Y; Zhang S; Li L; Zhou Y; Li J; Ma N; Li J; Li S; Gao X; Luo S
J Alzheimers Dis; 2015; 43(2):519-34. PubMed ID: 25114080
[TBL] [Abstract][Full Text] [Related]
30. Characteristics of TBS-extractable hyperphosphorylated tau species: aggregation intermediates in rTg4510 mouse brain.
Sahara N; DeTure M; Ren Y; Ebrahim AS; Kang D; Knight J; Volbracht C; Pedersen JT; Dickson DW; Yen SH; Lewis J
J Alzheimers Dis; 2013; 33(1):249-63. PubMed ID: 22941973
[TBL] [Abstract][Full Text] [Related]
31. Methods for measuring tau pathology in transgenic mouse models.
Forest SK; Acker CM; d'Abramo C; Davies P
J Alzheimers Dis; 2013; 33(2):463-71. PubMed ID: 22976073
[TBL] [Abstract][Full Text] [Related]
32. Cornel Iridoid Glycoside Suppresses Tau Hyperphosphorylation and Aggregation in a Mouse Model of Tauopathy through Increasing Activity of PP2A.
Ma D; Luo Y; Huang R; Zhao Z; Wang Q; Li L; Zhang L
Curr Alzheimer Res; 2019; 16(14):1316-1331. PubMed ID: 31902362
[TBL] [Abstract][Full Text] [Related]
33. IFN-γ promotes τ phosphorylation without affecting mature tangles.
Li A; Ceballos-Diaz C; DiNunno N; Levites Y; Cruz PE; Lewis J; Golde TE; Chakrabarty P
FASEB J; 2015 Oct; 29(10):4384-98. PubMed ID: 26156074
[TBL] [Abstract][Full Text] [Related]
34. Pazopanib Reduces Phosphorylated Tau Levels and Alters Astrocytes in a Mouse Model of Tauopathy.
Javidnia M; Hebron ML; Xin Y; Kinney NG; Moussa CE
J Alzheimers Dis; 2017; 60(2):461-481. PubMed ID: 28869476
[TBL] [Abstract][Full Text] [Related]
35. Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model.
Ando K; Leroy K; Héraud C; Yilmaz Z; Authelet M; Suain V; De Decker R; Brion JP
Am J Pathol; 2011 Feb; 178(2):803-16. PubMed ID: 21281813
[TBL] [Abstract][Full Text] [Related]
36. Biochemical isolation of insoluble tau in transgenic mouse models of tauopathies.
Julien C; Bretteville A; Planel E
Methods Mol Biol; 2012; 849():473-91. PubMed ID: 22528110
[TBL] [Abstract][Full Text] [Related]
37. The CNS in inbred transgenic models of 4-repeat Tauopathy develops consistent tau seeding capacity yet focal and diverse patterns of protein deposition.
Eskandari-Sedighi G; Daude N; Gapeshina H; Sanders DW; Kamali-Jamil R; Yang J; Shi B; Wille H; Ghetti B; Diamond MI; Janus C; Westaway D
Mol Neurodegener; 2017 Oct; 12(1):72. PubMed ID: 28978354
[TBL] [Abstract][Full Text] [Related]
38. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform.
Ishihara T; Hong M; Zhang B; Nakagawa Y; Lee MK; Trojanowski JQ; Lee VM
Neuron; 1999 Nov; 24(3):751-62. PubMed ID: 10595524
[TBL] [Abstract][Full Text] [Related]
39. Immunoelectron microscopic and biochemical studies of caspase-cleaved tau in a mouse model of tauopathy.
Lin WL; Dickson DW; Sahara N
J Neuropathol Exp Neurol; 2011 Sep; 70(9):779-87. PubMed ID: 21865886
[TBL] [Abstract][Full Text] [Related]
40. Methods for Biochemical Isolation of Insoluble Tau in Rodent Models of Tauopathies.
Canet G; Rocaboy E; Diego-Diàz S; Whittington RA; Julien C; Planel E
Methods Mol Biol; 2024; 2754():323-341. PubMed ID: 38512674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
